LGND Share Price

Open 102.27 Change Price %
High 105.11 1 Day 1.92 1.90
Low 102.04 1 Week -2.44 -2.31
Close 103.18 1 Month -0.91 -0.87
Volume 393702 1 Year 5.48 5.61
52 Week High 139.79
52 Week Low 82.06
LGND Important Levels
Resistance 2 106.03
Resistance 1 104.85
Pivot 103.44
Support 1 101.51
Support 2 100.33
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
DRYS 1.01 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
CPSL 0.10 66.67%
LOCM 0.09 50.00%
GLBS 9.70 31.79%
LTRE 2.85 29.55%
ETRM 7.96 29.22%
INFI 2.00 29.03%
QKLS 0.14 27.27%
PRKR 2.57 26.60%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
HEAT 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)

LGND Technical Analysis 3
As on 20th Jan 2017 LGND Share Price closed @ 103.18 and we RECOMMEND Sell for LONG-TERM with Stoploss of 110.39 & Sell for SHORT-TERM with Stoploss of 103.95 we also expect STOCK to react on Following IMPORTANT LEVELS.
LGND Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
LGND Other Details
Segment EQ
Market Capital 357465760.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.ligand.com
LGND Address
LGND
11119 North Torrey Pines Road
Suite 200
La Jolla, CA 92037
United States
Phone: 858-550-7500
Interactive Technical Analysis Chart Ligand Pharmaceuticals Incorporated ( LGND NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ligand Pharmaceuticals Incorporated
LGND Business Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring assets. The Company�s technology portfolio CAPTISOL is a formulation technology that has enabled five Food and Drug Administration (FDA) approved products, including Pfizer�s VFEND IV and Baxter International�s Nexterone and is being used in a number of clinical-stage partner programs. The therapies in its portfolio in development address the unmet medical needs of patients for a spectrum of diseases, including hepatitis, muscle wasting, Alzheimer�s disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis. It�s wholly owned subsidiaries include Ligand JVR, Allergan Ligand Retinoid Therapeutics, Seragen, Inc., Pharmacopeia, LLC, Neurogen Corporation, CyDex Pharmaceuticals, Inc. and Metabasis Therapeutics. On January 26, 2011, the Company acquired CyDex Pharmaceuticals, Inc. (CyDex).